Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe footer now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry have been removed. These changes do not affect the study information or page functionality.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no substantive changes to trial details, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedThe Publications section was updated: a sentence about voluntarily provided publications (revision 3.3.1) was added, and the previous sentence about study results (revision 3.2.0) was removed.SummaryDifference0.1%

- Check47 days agoChange DetectedRemoval of the government funding status banner. This does not change the study details, eligibility criteria, or enrollment information shown on the page.SummaryDifference0.3%

- Check61 days agoChange DetectedNo significant changes detected in the study record NCT04131543; the screenshots show the same study details with minor formatting changes and potentially updated timestamps. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check90 days agoChange DetectedKey update: page now warns about potential delays due to funding lapses and confirms the NIH Clinical Center is open, plus a version upgrade to v3.2.0.SummaryDifference2%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.